Elevated CSN6 may be prognostic for poor survival colorectal cancer
the ONA take:
A study from The University of Texas MD Anderson Cancer Center identified a protein, CSN6, a subunit of a protein complex known as COP9 signalsome, that correlated with poor survival in patients with colorectal cancer. The researchers found that elevated CSN6 is a biomarker for worse recurrence-free survival in patients with colon cancer.
CSN6 is normally regulated through the EGFR and ERK signaling pathways. When overexpressed via ERK2 in particular, it leads to deregulation of beta-catenin, a transcription factor known to be linked to cancer development.
The current standard of treatment for colorectal cancer in patients at high risk of recurrent or metastatic disease includes surgery, chemotherapy, and targeted therapies.
The researchers report that defining the molecular alterations can help guide treatment and improve clinical care.
CSN6, a subunit of a protein complex known as COP9 signalsome, correlated with poor survival in patients with colorectal cancer.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Recurrence Score Appears To Be Driving Personalized Treatment for Breast Cancer
- Smoking-related Cancer Deaths Highest in Southern United States
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|